๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shandong
Clinical trial register · China

Clinical Trials in Shandong, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca6 Xuanwu Hospital, Beijing2 Shandong Cancer Hospital and Institute2 Rongchang Pharmaceuticals Co., Ltd.1 Beijing Shijitan Hospital, Capital Medical University1
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shandong

29 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors
NCT07806175Advanced Malignant Solid Tumors
Rongchang Pharmaceuticals Co., Ltd.
Phase 1/2
486
Beijing, Hunan, Zhejiang, Shandong, Shanghai, Shanxi, Tianjin
2026-09-15
Recruiting
Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation Monitoring
NCT07747701Acute Ischemic Stroke, Cerebral Autoregulation
Beijing Shijitan Hospital, Capital Medical University
Not applicable
227
Beijing, Dalian, Heilongjiang, Shandong
2026-07-31
Recruiting
Chinese Adults With Kidney Disease
NCT07522099Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN
DrugTelitacicept
ADARx Pharmaceuticals, Inc.
Phase 2
30
Shenzhen, Guiyang, Zhengzhou, Baotou, Wuxi, Yantai, Beijing, Shandong
2026-05-21
Recruiting
Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion
NCT07519044Stroke, Acute Ischemic Stroke
Xuanwu Hospital, Beijing
Phase 4
868
Beijing, Shandong
2026-05-14
Recruiting
Prediction Model for MINS After Major Hepatobiliary Surgery
NCT07335042Myocardial Injury After Noncardiac Surgery (MINS), Postoperative Complications, Liver Neoplasm, Hepatobiliary Diseases
Beijing Tsinghua Chang Gung Hospital
Observational
1,800
Beijing, Chongqing, Qingdao, Shandong, Zhuhai
2026-01-14
Recruiting
Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
NCT07333274Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer
DrugNimotuzumab
Shandong Cancer Hospital and Institute
Phase 3
335
Shandong
2026-01-05
Recruiting
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
NCT07205822Breast Cancer
DrugDato-DXd
AstraZeneca
Phase 3
100
Beijing, Changsha, Guangzhou, Linyi, Shandong, Wuhan, Zhengzhou
2025-10-30
Recruiting
Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy
NCT07202559Pancreatitis, Chronic, Pancreatitis, Acute, Pancreatic Duct Stones
Changhai Hospital
Not applicable
1,250
Baotou, Beijing, Hangzhou, Hunan, Lanzhou, Shandong, Shanghai, Yunnan
2025-10-13
Recruiting
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
NCT07147348Advanced Solid Tumor
DrugPumitamig
BioNTech SE
Phase 1/2
375
Beijing, Hefei, Henan, Hunan, Shandong, Shanghai, Sichuan, Zhejiang
2025-08-27
Not yet open
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
NCT07093931Breast Cancer
DrugsLobaplatin·Albumin paclitaxel·Pertuzumab·Trastuzumab
Shandong Cancer Hospital and Institute
Phase 4
468
Shandong
2025-08-01
Not yet open
The Intraoperative Technical Errors of Robotic vs. Laparoscopic Radical Right Hemiclectomy
NCT07138859Colorectal Carcinoma (CRC), Right Hemicolectomy
The Affiliated Hospital of Qingdao University
Not applicable
368
Shandong
2025-08
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
Beijing, Chongqing, Zhejiang, Heilongjiang, Zhengzhou, Wuhan, Changsha, Shandong
2025-07-25
Recruiting
Early Prophylactic Decompressive Hemicraniectomy Following Endovascular Therapy in Large Hemispheric Infarct Trial
NCT07118345Stroke, Ischemic, Cerebral Edema
Xuanwu Hospital, Beijing
Not applicable
380
Beijing, Shandong
2025-07-19
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844Advanced Solid Tumors, Advanced Breast Cancer
DrugFulvestrant
Ensem Therapeutics
Phase 1/2
233
Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
2025-06-10
Recruiting
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
NCT06832982Advanced Solid Tumors
Shanghai Pushi Medical Science Co. Ltd
Phase 1
66
Beijing, Fujian, Zhejiang, Heilongjiang, Shandong, Guangdong, Shenyang, Hebei
2025-02-24
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Chengdu, Guangzhou, Nanchang, Nanjing, Nantong, Shandong, Shanghai, Tianjin
2024-11-27
Recruiting
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
NCT06956001EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)
DrugsFirmonertinib Mesilate·Pemetrexed Disodium·Cisplatin·Carboplatin
Allist Pharmaceuticals, Inc.
Phase 3
300
Beijing, Shandong
2024-11-19
Recruiting
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
NCT06238401Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase 1
77
Beijing, Zhejiang, Shandong, Shanghai
2024-10-29
Active, closed
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
NCT06244485Advanced Solid Tumor
DrugsValemetostat Tosylate·Dato-DXd·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 1
210
Beijing, Guangzhou, Heilongjiang, Hunan, Jilin City, Shandong
2024-02-22
Active, closed
Safety and Efficacy of CD19 CAR-T/CAR-NK Cells
NCT06596057Safety and Efficacy
The Second Hospital of Shandong University
Phase EARLY_PHASE1
10
Shandong
2024-02-10
Active, closed
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis๏ผšContezolid, Delamanid and Bedaquiline Cohort
NCT06081361Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
DrugsClofazimine·Delamanid·Bedaquiline·Contezolid
Beijing Chest Hospital
Phase 3
186
Beijing, Changsha, Hefei, Jiamusi, Shandong, Xi'an, Xinxiang, Shijiazhuang
2023-12-22
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
AstraZeneca
Phase 1/2
280
Beijing, Shandong
2023-07-11
Recruiting
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
NCT05607498Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma
EpimAb Biotherapeutics (Suzhou)Co., Ltd.
Phase 1
150
Changsha, Baoding, Beijing, Bengbu, Guangzhou, Harbin, Shandong, Tianjin
2023-03-01
Active, closed
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
NCT05514132Advanced Solid Tumours
DrugsCeralasertib·Durvalumab
AstraZeneca
Phase 1
14
Beijing, Shandong
2022-09-23
Recruiting
INSIGHTFUL-FFR Clinical Trial
NCT05437900Coronary Artery Disease, Acute Coronary Syndrome
CoreAalst BV
Phase 4
2,500
Shanghai, Shandong, Sichuan
2022-09-22
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797Multiple Myeloma
DrugsTeclistamab·Lenalidomide
European Myeloma Network B.V.
Phase 3
1,594
Beijing, Changchun, Henan, Shandong, Shanghai, Shenyang, Tangshan, Tianjin
2022-09-08
Recruiting
To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors
NCT05260385Digestive System Tumors
DrugKC1036
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 1/2
133
Beijing, Bengbu, Chongqing, Fujian, Henan, Hubei, Shandong, Shanghai
2022-01-24
Recruiting
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
DrugsPalacaparib·Saruparib·Rilvegostomig
AstraZeneca
Phase 1/2
460
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Shandong
2021-10-18
Recruiting
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
NCT04686305Locally Advanced or Metastatic Non-Small Cell Lung Cancer
DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Durvalumab
AstraZeneca
Phase 1
304
Changchun, Chengdu, Fuzhou, Shandong, Shanghai, Zhengzhou
2021-03-09
Rows per page Showing 1–29 of 29
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shandong

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 29 of those studies with a site in Shandong.

How many clinical trials are recruiting in Shandong?

22 of the 29 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shandong), 29 studies
PhaseStudiesRecruitingShare
Phase 17524.1%
Phase 1/26520.7%
Phase 35417.2%
Not applicable4313.8%
Phase 43210.3%
Phase 2226.9%
Observational113.4%
Phase EARLY_PHASE1103.4%

Most active sponsors

Lead sponsors with the most studies (Shandong)
Lead sponsorStudiesRecruiting
AstraZeneca65
Shandong Cancer Hospital and Institute21
Xuanwu Hospital, Beijing22
ADARx Pharmaceuticals, Inc.11
Allist Pharmaceuticals, Inc.11
ArriVent BioPharma, Inc.11
Beijing Chest Hospital10
Beijing Konruns Pharmaceutical Co., Ltd.11
Beijing Shijitan Hospital, Capital Medical University11
Beijing Tsinghua Chang Gung Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.